MUMBAI, India, Aug. 22 -- Intellectual Property India has published a patent application (202421010878 A) filed by Onecell Diagnostics India Private Limited; and Onecell Diagnostics, Inc., Pune, Maharashtra, on Feb. 16, 2024, for 'a method for selecting ovarian cancer patients for parp inhibitor treatment.'
Inventor(s) include Mohan Uttarwar; Gowhar Shafi; P M Shivamurthy; Anand Raj Ulle; Chongtham Cha Chinglemba; and Jayant Jagannath Khandare.
The application for the patent was published on Aug. 22, under issue no. 34/2025.
According to the abstract released by the Intellectual Property India: "The present disclosure relates to a method for selection of ovarian cancer patients for treatment with PARP inhibitors. This involves 1) preparing whole slide images of tissues of ovarian cancer patient to be treated 2) training and validating AI model built on Resnet-50 to recognize morphological features from tiles of hematoxylin and eosin stained whole slide images of tissues featuring the presence of homologous recombination deficiency as annotated by next generation sequencing 3) using the model to extract morphological features from the tiles of hematoxylin and eosin stained whole slide images of tissues of ovarian cancer patients, generating tile level predictions, aggregating tile level predictions to generate a probability score and selecting the patient for treatment with PARP inhibitors 4) administering PARP inhibitors treatment to the patient selected based on probability score reaching a predetermined threshold. Computer systems to implement the method are also disclosed."
Disclaimer: Curated by HT Syndication.
